View ValuationThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsAdderaCare 将来の成長Future 基準チェック /36主要情報82.8%収益成長率81.36%EPS成長率Medical Equipment 収益成長21.6%収益成長率4.6%将来の株主資本利益率0.91%アナリストカバレッジLow最終更新日n/a今後の成長に関する最新情報Price Target Changed • Nov 16Price target decreased to kr4.30Down from kr4.80, the current price target is provided by 1 analyst. New target price is 41% above last closing price of kr3.05. Stock is down 42% over the past year. The company is forecast to post a net loss per share of kr0.84 compared to earnings per share of kr0.037 last year.Major Estimate Revision • Aug 27Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast increased from kr266.7m to kr272.1m. Forecast EPS reduced from -kr0.65 to -kr0.84 per share. Medical Equipment industry in Sweden expected to see average net income growth of 29% next year. Consensus price target down from kr4.80 to kr4.30. Share price rose 4.4% to kr2.37 over the past week.Price Target Changed • Aug 27Price target decreased to kr4.30Down from kr4.80, the current price target is provided by 1 analyst. New target price is 81% above last closing price of kr2.37. Stock is down 65% over the past year. The company is forecast to post a net loss per share of kr0.84 compared to earnings per share of kr0.037 last year.Major Estimate Revision • Jun 18Consensus EPS estimates have been downgraded.The consensus outlook for earnings per share (EPS) in 2022 has deteriorated. 2022 revenue forecast decreased from kr278.0m to kr266.7m. Now expected to report a loss of kr0.65 per share instead of kr0.04 per share profit previously forecast. Medical Equipment industry in Sweden expected to see average net income growth of 30% next year. Consensus price target down from kr4.95 to kr4.80. Share price fell 14% to kr2.58 over the past week.Major Estimate Revision • May 26Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast increased from kr270.1m to kr278.0m. EPS estimate fell from kr0.24 to kr0.04 per share. Net income forecast to shrink 86% next year vs 30% growth forecast for Medical Equipment industry in Sweden . Consensus price target down from kr7.05 to kr4.95. Share price was steady at kr3.03 over the past week.Price Target Changed • May 24Price target decreased to kr4.95Down from kr7.05, the current price target is provided by 1 analyst. New target price is 70% above last closing price of kr2.92. Stock is down 54% over the past year. The company is forecast to post earnings per share of kr0.04 for next year compared to kr0.037 last year.すべての更新を表示Recent updatesお知らせ • Jan 11AdderaCare's Directors Applied for the Delisting of Its Shares from Nasdaq StockholmMedCap secured about a 97.16% shareholding in AdderaCare AB after its recommended public offer was extended until January 9, 2023. The Swedish private equity company said on January 6, 2023 it launched the compulsory acquisition of the remaining shares and the settlement for shares tendered during the extension is expected to start around January 16, 2023. AdderaCare's directors applied for the delisting of its shares from Nasdaq Stockholm and the last day of trading is January 20, 2023.お知らせ • Jan 05AdderaCare AB to Apply for Delisting of Its Shares from Nasdaq First North Growth MarketOn November 17, 2022, the shares in AdderaCare AB (the Company) were given observation status with reference to a public takeover offer from MedCap AB (publ) (“MedCap”) to the shareholders in the Company. On December 23, 2022, MedCap issued a press release with information that MedCap had achieved control of more than 90% of the shares in the Company. The press release also stated that MedCap intended to commence a compulsory acquisition procedure to acquire the remaining shares in the Company, and to seek a delisting of the Company’s shares from Nasdaq First North Growth Market. On January 4, 2023, the Company issued a press release with information that the Company had decided to apply for delisting of its shares from Nasdaq First North Growth Market. Nasdaq Stockholm AB has also received such an application from the Company.お知らせ • Nov 17MedCap May Promote Delisting of AdderaCar's Shares from Nasdaq First North Growth MarketMedCap AB (publ) announced a recommended public cash offer to the shareholders of AdderaCare AB (AdderaCare AB (publ)) ("Company") to tender all their shares in AdderaCare to MedCap at a price of SEK 3.60 in cash per share (the "Offer"). The shares in AdderaCare are admitted to trading on Nasdaq First North Growth Market, under the ticker ADDERA. In the event that MedCap, whether in connection with the Offer or otherwise, acquires shares representing more than 90% of the total number of shares of AdderaCare, MedCap intends to initiate a compulsory buy-out procedure with respect to the remaining shares. In connection therewith, MedCap may promote delisting of AdderaCare's shares from Nasdaq First North Growth Market.Price Target Changed • Nov 16Price target decreased to kr4.30Down from kr4.80, the current price target is provided by 1 analyst. New target price is 41% above last closing price of kr3.05. Stock is down 42% over the past year. The company is forecast to post a net loss per share of kr0.84 compared to earnings per share of kr0.037 last year.Valuation Update With 7 Day Price Move • Sep 01Investor sentiment improved over the past weekAfter last week's 21% share price gain to kr2.60, the stock trades at a trailing P/E ratio of 17.8x. Average forward P/E is 17x in the Medical Equipment industry in Sweden. Total loss to shareholders of 45% over the past three years.分析記事 • Aug 31Is Now An Opportune Moment To Examine AdderaCare AB (STO:ADDERA)?AdderaCare AB ( STO:ADDERA ), is not the largest company out there, but it saw a double-digit share price rise of over...Major Estimate Revision • Aug 27Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast increased from kr266.7m to kr272.1m. Forecast EPS reduced from -kr0.65 to -kr0.84 per share. Medical Equipment industry in Sweden expected to see average net income growth of 29% next year. Consensus price target down from kr4.80 to kr4.30. Share price rose 4.4% to kr2.37 over the past week.Price Target Changed • Aug 27Price target decreased to kr4.30Down from kr4.80, the current price target is provided by 1 analyst. New target price is 81% above last closing price of kr2.37. Stock is down 65% over the past year. The company is forecast to post a net loss per share of kr0.84 compared to earnings per share of kr0.037 last year.Valuation Update With 7 Day Price Move • Jun 21Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to kr2.44, the stock trades at a trailing P/E ratio of 16.7x. Average forward P/E is 20x in the Medical Equipment industry in Sweden. Total loss to shareholders of 57% over the past three years.Major Estimate Revision • Jun 18Consensus EPS estimates have been downgraded.The consensus outlook for earnings per share (EPS) in 2022 has deteriorated. 2022 revenue forecast decreased from kr278.0m to kr266.7m. Now expected to report a loss of kr0.65 per share instead of kr0.04 per share profit previously forecast. Medical Equipment industry in Sweden expected to see average net income growth of 30% next year. Consensus price target down from kr4.95 to kr4.80. Share price fell 14% to kr2.58 over the past week.分析記事 • Jun 18We Think AdderaCare (STO:ADDERA) Can Stay On Top Of Its DebtLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Major Estimate Revision • May 26Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast increased from kr270.1m to kr278.0m. EPS estimate fell from kr0.24 to kr0.04 per share. Net income forecast to shrink 86% next year vs 30% growth forecast for Medical Equipment industry in Sweden . Consensus price target down from kr7.05 to kr4.95. Share price was steady at kr3.03 over the past week.Price Target Changed • May 24Price target decreased to kr4.95Down from kr7.05, the current price target is provided by 1 analyst. New target price is 70% above last closing price of kr2.92. Stock is down 54% over the past year. The company is forecast to post earnings per share of kr0.04 for next year compared to kr0.037 last year.Reported Earnings • May 21First quarter 2022 earnings: Revenues exceed analyst expectationsFirst quarter 2022 results: Revenue: kr68.4m (up 51% from 1Q 2021). Net income: kr306.0k (up kr3.70m from 1Q 2021). Profit margin: 0.4% (up from net loss in 1Q 2021). The move to profitability was driven by higher revenue. Revenue exceeded analyst estimates by 7.3%. Over the next year, revenue is forecast to grow 3.3%, compared to a 126% growth forecast for the industry in Sweden. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings.Board Change • Apr 27Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. 1 independent director (4 non-independent directors). Chairman of the Board Hans Andersson is the most experienced director on the board, commencing their role in 2019. Independent Director Bengt Olsson was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.分析記事 • Apr 06Investors Could Be Concerned With AdderaCare's (STO:ADDERA) Returns On CapitalThere are a few key trends to look for if we want to identify the next multi-bagger. Ideally, a business will show two...Major Estimate Revision • Mar 03Consensus EPS estimates increase by 243%The consensus outlook for earnings per share (EPS) in 2022 has improved. 2022 revenue forecast increased from kr265.0m to kr270.1m. EPS estimate increased from kr0.07 to kr0.24 per share. Net income forecast to grow 545% next year vs 26% growth forecast for Medical Equipment industry in Sweden. Consensus price target up from kr6.90 to kr7.05. Share price rose 7.4% to kr4.22 over the past week.Reported Earnings • Feb 28Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2021 results: EPS: kr0.037 (down from kr0.45 in FY 2020). Revenue: kr247.8m (up 21% from FY 2020). Net income: kr1.24m (down 88% from FY 2020). Profit margin: 0.5% (down from 4.9% in FY 2020). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 7.3%. Earnings per share (EPS) also surpassed analyst estimates. Over the next year, revenue is forecast to grow 6.9%, compared to a 84% growth forecast for the industry in Sweden. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.分析記事 • Jan 27AdderaCare (STO:ADDERA) Has A Pretty Healthy Balance SheetHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...分析記事 • Nov 20AdderaCare (STO:ADDERA) Will Want To Turn Around Its Return TrendsIf you're looking for a multi-bagger, there's a few things to keep an eye out for. One common approach is to try and...Reported Earnings • Nov 14Third quarter 2021 earnings releasedThe company reported a soft third quarter result with weaker earnings and profit margins, although revenues improved. Third quarter 2021 results: Revenue: kr61.1m (up 20% from 3Q 2020). Net income: kr178.0k (down 90% from 3Q 2020). Profit margin: 0.3% (down from 3.5% in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.Price Target Changed • Nov 12Price target decreased to kr6.90Down from kr7.45, the current price target is provided by 1 analyst. New target price is 21% above last closing price of kr5.70. Stock is up 63% over the past year. The company is forecast to post earnings per share of kr0.02 for next year compared to kr0.45 last year.Reported Earnings • Aug 29Second quarter 2021 earnings releasedThe company reported a mediocre second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2021 results: Revenue: kr61.6m (up 41% from 2Q 2020). Net income: kr418.0k (down 96% from 2Q 2020). Profit margin: 0.7% (down from 21% in 2Q 2020). Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.分析記事 • Aug 29These 4 Measures Indicate That AdderaCare (STO:ADDERA) Is Using Debt Reasonably WellSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Valuation Update With 7 Day Price Move • Aug 04Investor sentiment improved over the past weekAfter last week's 16% share price gain to kr7.10, the stock trades at a trailing P/E ratio of 17.8x. Average forward P/E is 36x in the Medical Equipment industry in Sweden. Negligible returns to shareholders over past three years.分析記事 • Aug 02AdderaCare (STO:ADDERA) Could Be Struggling To Allocate CapitalWhat trends should we look for it we want to identify stocks that can multiply in value over the long term? Firstly...分析記事 • May 24What Does AdderaCare AB's (STO:ADDERA) Share Price Indicate?AdderaCare AB ( STO:ADDERA ), is not the largest company out there, but it saw a significant share price rise of over...Reported Earnings • May 15First quarter 2021 earnings releasedThe company reported a decent first quarter result with reduced losses and improved control over expenses, although revenues were weaker. First quarter 2021 results: Revenue: kr45.4m (down 5.3% from 1Q 2020). Net loss: kr3.39m (loss narrowed 10% from 1Q 2020). Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.分析記事 • Apr 28Here's What's Concerning About AdderaCare's (STO:ADDERA) Returns On CapitalFinding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...Valuation Update With 7 Day Price Move • Mar 18Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to kr6.25, the stock trades at a trailing P/E ratio of 13.9x. Average forward P/E is 29x in the Medical Equipment industry in Sweden. Total loss to shareholders of 30% over the past three years.分析記事 • Mar 03We Think That There Are Some Issues For AdderaCare (STO:ADDERA) Beyond Its Promising EarningsAdderaCare AB ( STO:ADDERA ) just released a solid earnings report, and the stock displayed some strength. However, we...Reported Earnings • Feb 28Full year 2020 earnings released: EPS kr0.38 (vs kr0.10 loss in FY 2019)The company reported a decent full year result with improved earnings and profit margins, although revenues were flat. Full year 2020 results: Revenue: kr205.2m (flat on FY 2019). Net income: kr9.96m (up kr11.8m from FY 2019). Profit margin: 4.9% (up from net loss in FY 2019). Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.Analyst Estimate Surprise Post Earnings • Feb 28Revenue beats expectationsRevenue exceeded analyst estimates by 3.9%. Over the next year, revenue is forecast to grow 5.7%, compared to a 452% growth forecast for the Medical Equipment industry in Sweden.Is New 90 Day High Low • Feb 25New 90-day high: kr6.10The company is up 71% from its price of kr3.56 on 27 November 2020. The Swedish market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 11% over the same period.Valuation Update With 7 Day Price Move • Feb 25Investor sentiment improved over the past weekAfter last week's 16% share price gain to kr6.10, the stock is trading at a trailing P/E ratio of 27x, up from the previous P/E ratio of 23.3x. This compares to an average P/E of 43x in the Medical Equipment industry in Sweden. Total return to shareholders over the past three years is a loss of 30%.分析記事 • Feb 20Is There Now An Opportunity In AdderaCare AB (STO:ADDERA)?AdderaCare AB ( STO:ADDERA ), might not be a large cap stock, but it led the OM gainers with a relatively large price...Valuation Update With 7 Day Price Move • Feb 02Investor sentiment improved over the past weekAfter last week's 22% share price gain to kr5.20, the stock is trading at a trailing P/E ratio of 23x, up from the previous P/E ratio of 18.9x. This compares to an average P/E of 36x in the Medical Equipment industry in Sweden. Total return to shareholders over the past three years is a loss of 47%.Is New 90 Day High Low • Feb 02New 90-day high: kr5.20The company is up 56% from its price of kr3.34 on 03 November 2020. The Swedish market is up 14% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 19% over the same period.分析記事 • Jan 16We Think AdderaCare (STO:ADDERA) Has A Fair Chunk Of DebtWarren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Is New 90 Day High Low • Jan 04New 90-day high: kr4.74The company is up 44% from its price of kr3.30 on 06 October 2020. The Swedish market is up 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 12% over the same period.Is New 90 Day High Low • Dec 16New 90-day high: kr4.28The company is up 25% from its price of kr3.42 on 16 September 2020. The Swedish market is up 4.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 3.0% over the same period.Valuation Update With 7 Day Price Move • Dec 08Market bids up stock over the past weekAfter last week's 20% share price gain to kr4.20, the stock is trading at a trailing P/E ratio of 18.6x, up from the previous P/E ratio of 15.5x. This compares to an average P/E of 33x in the Medical Equipment industry in Sweden. Total return to shareholders over the past three years is a loss of 58%.Valuation Update With 7 Day Price Move • Dec 02Market bids up stock over the past weekAfter last week's 22% share price gain to kr4.20, the stock is trading at a trailing P/E ratio of 18.6x, up from the previous P/E ratio of 15.2x. This compares to an average P/E of 32x in the Medical Equipment industry in Sweden. Total return to shareholders over the past three years is a loss of 61%.Is New 90 Day High Low • Nov 30New 90-day high: kr3.60The company is up 3.0% from its price of kr3.50 on 01 September 2020. The Swedish market is up 9.0% over the last 90 days, indicating the company underperformed over that time. However, its price trend is similar to the Medical Equipment industry, which is also up 3.0% over the same period.分析記事 • Nov 22Is It Time To Consider Buying AdderaCare AB (STO:ADDERA)?While AdderaCare AB (STO:ADDERA) might not be the most widely known stock at the moment, it saw a significant share...業績と収益の成長予測OM:ADDERA - アナリストの将来予測と過去の財務データ ( )SEK Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20253082N/A23112/31/2024307-1N/A15112/31/2023282-1N/A14112/31/2022259-29N/A1919/30/2022279-27911N/A6/30/2022283-251719N/A3/31/202227151619N/A12/31/202124811416N/A9/30/202123101214N/A6/30/20212212911N/A3/31/2021203101415N/A12/31/2020205101416N/A9/30/202019851414N/A6/30/2020199577N/A3/31/2020208-456N/A12/31/2019206-278N/A9/30/2019206358N/A6/30/201920111012N/A3/31/2019203379N/A12/31/201819212124N/A9/30/2018177179N/A6/30/201816111215N/A3/31/2018136-12226N/A12/31/20171284913N/A9/30/201711651621N/A6/30/20171054-23N/A3/31/20171027-8-6N/A12/31/2016946-10-9N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: ADDERAは今後 3 年間で収益性が向上すると予測されており、これは 貯蓄率 ( 0.4% ) よりも高い成長率であると考えられます。収益対市場: ADDERA今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。高成長収益: ADDERA今後 3 年以内に収益を上げることが予想されます。収益対市場: ADDERAの収益 ( 4.6% ) Swedish市場 ( -0.4% ) よりも低い成長が予測されています。高い収益成長: ADDERAの収益 ( 4.6% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: ADDERAの 自己資本利益率 は、3年後には低くなると予測されています ( 0.9 %)。成長企業の発掘7D1Y7D1Y7D1YHealthcare 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2023/01/12 14:30終値2023/01/12 00:00収益2022/09/30年間収益2021/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋AdderaCare AB 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Mats HyttingeCarlsquare AB
Price Target Changed • Nov 16Price target decreased to kr4.30Down from kr4.80, the current price target is provided by 1 analyst. New target price is 41% above last closing price of kr3.05. Stock is down 42% over the past year. The company is forecast to post a net loss per share of kr0.84 compared to earnings per share of kr0.037 last year.
Major Estimate Revision • Aug 27Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast increased from kr266.7m to kr272.1m. Forecast EPS reduced from -kr0.65 to -kr0.84 per share. Medical Equipment industry in Sweden expected to see average net income growth of 29% next year. Consensus price target down from kr4.80 to kr4.30. Share price rose 4.4% to kr2.37 over the past week.
Price Target Changed • Aug 27Price target decreased to kr4.30Down from kr4.80, the current price target is provided by 1 analyst. New target price is 81% above last closing price of kr2.37. Stock is down 65% over the past year. The company is forecast to post a net loss per share of kr0.84 compared to earnings per share of kr0.037 last year.
Major Estimate Revision • Jun 18Consensus EPS estimates have been downgraded.The consensus outlook for earnings per share (EPS) in 2022 has deteriorated. 2022 revenue forecast decreased from kr278.0m to kr266.7m. Now expected to report a loss of kr0.65 per share instead of kr0.04 per share profit previously forecast. Medical Equipment industry in Sweden expected to see average net income growth of 30% next year. Consensus price target down from kr4.95 to kr4.80. Share price fell 14% to kr2.58 over the past week.
Major Estimate Revision • May 26Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast increased from kr270.1m to kr278.0m. EPS estimate fell from kr0.24 to kr0.04 per share. Net income forecast to shrink 86% next year vs 30% growth forecast for Medical Equipment industry in Sweden . Consensus price target down from kr7.05 to kr4.95. Share price was steady at kr3.03 over the past week.
Price Target Changed • May 24Price target decreased to kr4.95Down from kr7.05, the current price target is provided by 1 analyst. New target price is 70% above last closing price of kr2.92. Stock is down 54% over the past year. The company is forecast to post earnings per share of kr0.04 for next year compared to kr0.037 last year.
お知らせ • Jan 11AdderaCare's Directors Applied for the Delisting of Its Shares from Nasdaq StockholmMedCap secured about a 97.16% shareholding in AdderaCare AB after its recommended public offer was extended until January 9, 2023. The Swedish private equity company said on January 6, 2023 it launched the compulsory acquisition of the remaining shares and the settlement for shares tendered during the extension is expected to start around January 16, 2023. AdderaCare's directors applied for the delisting of its shares from Nasdaq Stockholm and the last day of trading is January 20, 2023.
お知らせ • Jan 05AdderaCare AB to Apply for Delisting of Its Shares from Nasdaq First North Growth MarketOn November 17, 2022, the shares in AdderaCare AB (the Company) were given observation status with reference to a public takeover offer from MedCap AB (publ) (“MedCap”) to the shareholders in the Company. On December 23, 2022, MedCap issued a press release with information that MedCap had achieved control of more than 90% of the shares in the Company. The press release also stated that MedCap intended to commence a compulsory acquisition procedure to acquire the remaining shares in the Company, and to seek a delisting of the Company’s shares from Nasdaq First North Growth Market. On January 4, 2023, the Company issued a press release with information that the Company had decided to apply for delisting of its shares from Nasdaq First North Growth Market. Nasdaq Stockholm AB has also received such an application from the Company.
お知らせ • Nov 17MedCap May Promote Delisting of AdderaCar's Shares from Nasdaq First North Growth MarketMedCap AB (publ) announced a recommended public cash offer to the shareholders of AdderaCare AB (AdderaCare AB (publ)) ("Company") to tender all their shares in AdderaCare to MedCap at a price of SEK 3.60 in cash per share (the "Offer"). The shares in AdderaCare are admitted to trading on Nasdaq First North Growth Market, under the ticker ADDERA. In the event that MedCap, whether in connection with the Offer or otherwise, acquires shares representing more than 90% of the total number of shares of AdderaCare, MedCap intends to initiate a compulsory buy-out procedure with respect to the remaining shares. In connection therewith, MedCap may promote delisting of AdderaCare's shares from Nasdaq First North Growth Market.
Price Target Changed • Nov 16Price target decreased to kr4.30Down from kr4.80, the current price target is provided by 1 analyst. New target price is 41% above last closing price of kr3.05. Stock is down 42% over the past year. The company is forecast to post a net loss per share of kr0.84 compared to earnings per share of kr0.037 last year.
Valuation Update With 7 Day Price Move • Sep 01Investor sentiment improved over the past weekAfter last week's 21% share price gain to kr2.60, the stock trades at a trailing P/E ratio of 17.8x. Average forward P/E is 17x in the Medical Equipment industry in Sweden. Total loss to shareholders of 45% over the past three years.
分析記事 • Aug 31Is Now An Opportune Moment To Examine AdderaCare AB (STO:ADDERA)?AdderaCare AB ( STO:ADDERA ), is not the largest company out there, but it saw a double-digit share price rise of over...
Major Estimate Revision • Aug 27Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast increased from kr266.7m to kr272.1m. Forecast EPS reduced from -kr0.65 to -kr0.84 per share. Medical Equipment industry in Sweden expected to see average net income growth of 29% next year. Consensus price target down from kr4.80 to kr4.30. Share price rose 4.4% to kr2.37 over the past week.
Price Target Changed • Aug 27Price target decreased to kr4.30Down from kr4.80, the current price target is provided by 1 analyst. New target price is 81% above last closing price of kr2.37. Stock is down 65% over the past year. The company is forecast to post a net loss per share of kr0.84 compared to earnings per share of kr0.037 last year.
Valuation Update With 7 Day Price Move • Jun 21Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to kr2.44, the stock trades at a trailing P/E ratio of 16.7x. Average forward P/E is 20x in the Medical Equipment industry in Sweden. Total loss to shareholders of 57% over the past three years.
Major Estimate Revision • Jun 18Consensus EPS estimates have been downgraded.The consensus outlook for earnings per share (EPS) in 2022 has deteriorated. 2022 revenue forecast decreased from kr278.0m to kr266.7m. Now expected to report a loss of kr0.65 per share instead of kr0.04 per share profit previously forecast. Medical Equipment industry in Sweden expected to see average net income growth of 30% next year. Consensus price target down from kr4.95 to kr4.80. Share price fell 14% to kr2.58 over the past week.
分析記事 • Jun 18We Think AdderaCare (STO:ADDERA) Can Stay On Top Of Its DebtLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Major Estimate Revision • May 26Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast increased from kr270.1m to kr278.0m. EPS estimate fell from kr0.24 to kr0.04 per share. Net income forecast to shrink 86% next year vs 30% growth forecast for Medical Equipment industry in Sweden . Consensus price target down from kr7.05 to kr4.95. Share price was steady at kr3.03 over the past week.
Price Target Changed • May 24Price target decreased to kr4.95Down from kr7.05, the current price target is provided by 1 analyst. New target price is 70% above last closing price of kr2.92. Stock is down 54% over the past year. The company is forecast to post earnings per share of kr0.04 for next year compared to kr0.037 last year.
Reported Earnings • May 21First quarter 2022 earnings: Revenues exceed analyst expectationsFirst quarter 2022 results: Revenue: kr68.4m (up 51% from 1Q 2021). Net income: kr306.0k (up kr3.70m from 1Q 2021). Profit margin: 0.4% (up from net loss in 1Q 2021). The move to profitability was driven by higher revenue. Revenue exceeded analyst estimates by 7.3%. Over the next year, revenue is forecast to grow 3.3%, compared to a 126% growth forecast for the industry in Sweden. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings.
Board Change • Apr 27Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. 1 independent director (4 non-independent directors). Chairman of the Board Hans Andersson is the most experienced director on the board, commencing their role in 2019. Independent Director Bengt Olsson was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
分析記事 • Apr 06Investors Could Be Concerned With AdderaCare's (STO:ADDERA) Returns On CapitalThere are a few key trends to look for if we want to identify the next multi-bagger. Ideally, a business will show two...
Major Estimate Revision • Mar 03Consensus EPS estimates increase by 243%The consensus outlook for earnings per share (EPS) in 2022 has improved. 2022 revenue forecast increased from kr265.0m to kr270.1m. EPS estimate increased from kr0.07 to kr0.24 per share. Net income forecast to grow 545% next year vs 26% growth forecast for Medical Equipment industry in Sweden. Consensus price target up from kr6.90 to kr7.05. Share price rose 7.4% to kr4.22 over the past week.
Reported Earnings • Feb 28Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2021 results: EPS: kr0.037 (down from kr0.45 in FY 2020). Revenue: kr247.8m (up 21% from FY 2020). Net income: kr1.24m (down 88% from FY 2020). Profit margin: 0.5% (down from 4.9% in FY 2020). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 7.3%. Earnings per share (EPS) also surpassed analyst estimates. Over the next year, revenue is forecast to grow 6.9%, compared to a 84% growth forecast for the industry in Sweden. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.
分析記事 • Jan 27AdderaCare (STO:ADDERA) Has A Pretty Healthy Balance SheetHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
分析記事 • Nov 20AdderaCare (STO:ADDERA) Will Want To Turn Around Its Return TrendsIf you're looking for a multi-bagger, there's a few things to keep an eye out for. One common approach is to try and...
Reported Earnings • Nov 14Third quarter 2021 earnings releasedThe company reported a soft third quarter result with weaker earnings and profit margins, although revenues improved. Third quarter 2021 results: Revenue: kr61.1m (up 20% from 3Q 2020). Net income: kr178.0k (down 90% from 3Q 2020). Profit margin: 0.3% (down from 3.5% in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.
Price Target Changed • Nov 12Price target decreased to kr6.90Down from kr7.45, the current price target is provided by 1 analyst. New target price is 21% above last closing price of kr5.70. Stock is up 63% over the past year. The company is forecast to post earnings per share of kr0.02 for next year compared to kr0.45 last year.
Reported Earnings • Aug 29Second quarter 2021 earnings releasedThe company reported a mediocre second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2021 results: Revenue: kr61.6m (up 41% from 2Q 2020). Net income: kr418.0k (down 96% from 2Q 2020). Profit margin: 0.7% (down from 21% in 2Q 2020). Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.
分析記事 • Aug 29These 4 Measures Indicate That AdderaCare (STO:ADDERA) Is Using Debt Reasonably WellSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Valuation Update With 7 Day Price Move • Aug 04Investor sentiment improved over the past weekAfter last week's 16% share price gain to kr7.10, the stock trades at a trailing P/E ratio of 17.8x. Average forward P/E is 36x in the Medical Equipment industry in Sweden. Negligible returns to shareholders over past three years.
分析記事 • Aug 02AdderaCare (STO:ADDERA) Could Be Struggling To Allocate CapitalWhat trends should we look for it we want to identify stocks that can multiply in value over the long term? Firstly...
分析記事 • May 24What Does AdderaCare AB's (STO:ADDERA) Share Price Indicate?AdderaCare AB ( STO:ADDERA ), is not the largest company out there, but it saw a significant share price rise of over...
Reported Earnings • May 15First quarter 2021 earnings releasedThe company reported a decent first quarter result with reduced losses and improved control over expenses, although revenues were weaker. First quarter 2021 results: Revenue: kr45.4m (down 5.3% from 1Q 2020). Net loss: kr3.39m (loss narrowed 10% from 1Q 2020). Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.
分析記事 • Apr 28Here's What's Concerning About AdderaCare's (STO:ADDERA) Returns On CapitalFinding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...
Valuation Update With 7 Day Price Move • Mar 18Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to kr6.25, the stock trades at a trailing P/E ratio of 13.9x. Average forward P/E is 29x in the Medical Equipment industry in Sweden. Total loss to shareholders of 30% over the past three years.
分析記事 • Mar 03We Think That There Are Some Issues For AdderaCare (STO:ADDERA) Beyond Its Promising EarningsAdderaCare AB ( STO:ADDERA ) just released a solid earnings report, and the stock displayed some strength. However, we...
Reported Earnings • Feb 28Full year 2020 earnings released: EPS kr0.38 (vs kr0.10 loss in FY 2019)The company reported a decent full year result with improved earnings and profit margins, although revenues were flat. Full year 2020 results: Revenue: kr205.2m (flat on FY 2019). Net income: kr9.96m (up kr11.8m from FY 2019). Profit margin: 4.9% (up from net loss in FY 2019). Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.
Analyst Estimate Surprise Post Earnings • Feb 28Revenue beats expectationsRevenue exceeded analyst estimates by 3.9%. Over the next year, revenue is forecast to grow 5.7%, compared to a 452% growth forecast for the Medical Equipment industry in Sweden.
Is New 90 Day High Low • Feb 25New 90-day high: kr6.10The company is up 71% from its price of kr3.56 on 27 November 2020. The Swedish market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 11% over the same period.
Valuation Update With 7 Day Price Move • Feb 25Investor sentiment improved over the past weekAfter last week's 16% share price gain to kr6.10, the stock is trading at a trailing P/E ratio of 27x, up from the previous P/E ratio of 23.3x. This compares to an average P/E of 43x in the Medical Equipment industry in Sweden. Total return to shareholders over the past three years is a loss of 30%.
分析記事 • Feb 20Is There Now An Opportunity In AdderaCare AB (STO:ADDERA)?AdderaCare AB ( STO:ADDERA ), might not be a large cap stock, but it led the OM gainers with a relatively large price...
Valuation Update With 7 Day Price Move • Feb 02Investor sentiment improved over the past weekAfter last week's 22% share price gain to kr5.20, the stock is trading at a trailing P/E ratio of 23x, up from the previous P/E ratio of 18.9x. This compares to an average P/E of 36x in the Medical Equipment industry in Sweden. Total return to shareholders over the past three years is a loss of 47%.
Is New 90 Day High Low • Feb 02New 90-day high: kr5.20The company is up 56% from its price of kr3.34 on 03 November 2020. The Swedish market is up 14% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 19% over the same period.
分析記事 • Jan 16We Think AdderaCare (STO:ADDERA) Has A Fair Chunk Of DebtWarren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
Is New 90 Day High Low • Jan 04New 90-day high: kr4.74The company is up 44% from its price of kr3.30 on 06 October 2020. The Swedish market is up 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 12% over the same period.
Is New 90 Day High Low • Dec 16New 90-day high: kr4.28The company is up 25% from its price of kr3.42 on 16 September 2020. The Swedish market is up 4.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 3.0% over the same period.
Valuation Update With 7 Day Price Move • Dec 08Market bids up stock over the past weekAfter last week's 20% share price gain to kr4.20, the stock is trading at a trailing P/E ratio of 18.6x, up from the previous P/E ratio of 15.5x. This compares to an average P/E of 33x in the Medical Equipment industry in Sweden. Total return to shareholders over the past three years is a loss of 58%.
Valuation Update With 7 Day Price Move • Dec 02Market bids up stock over the past weekAfter last week's 22% share price gain to kr4.20, the stock is trading at a trailing P/E ratio of 18.6x, up from the previous P/E ratio of 15.2x. This compares to an average P/E of 32x in the Medical Equipment industry in Sweden. Total return to shareholders over the past three years is a loss of 61%.
Is New 90 Day High Low • Nov 30New 90-day high: kr3.60The company is up 3.0% from its price of kr3.50 on 01 September 2020. The Swedish market is up 9.0% over the last 90 days, indicating the company underperformed over that time. However, its price trend is similar to the Medical Equipment industry, which is also up 3.0% over the same period.
分析記事 • Nov 22Is It Time To Consider Buying AdderaCare AB (STO:ADDERA)?While AdderaCare AB (STO:ADDERA) might not be the most widely known stock at the moment, it saw a significant share...